<p>09/03/2024 - 上午 09:41</p>
<p><em>Owlet 在 Kind + Jugend 2024 展会上推出新款 Dream Sock，并表示该设备将很快在全球更多地区推出。</em></p>
<p>犹他州 LEHI--(商业线)--Owlet 公司（“Owlet” 或 “公司”）（NYSE:OWLT），智能婴儿监测的先驱者，今天在德国科隆举行的 Kind + Jugend 展会上宣布，医疗认证的 Dream Sock 将很快在更多国家推出，包括波兰、希腊和捷克共和国。Dream Sock 是该公司在欧洲推出的医疗认证婴儿监测器，为父母在婴儿睡眠时提供安全准确的健康数据和可操作的警报。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20240903971490/en/2231017/4/dream_sock_2.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20240903971490/en/2231017/4/dream_sock_2.jpg"/></p>
<p>Owlet Dream Sock（图片：商业线）</p>
<p>Owlet 首席执行官兼联合创始人 Kurt Workman 表示：“自全球推出几个月以来，Dream Sock 已经对成千上万个家庭产生了巨大影响，我们渴望继续将我们的医疗级技术推广给更多父母。我们本周参加 Kind + Jugend 展会，与现有和潜在的分销合作伙伴会面，展示我们的最新技术，并展示 Owlet 在全球产生的影响。”</p>
<p>Dream Sock 在欧盟和英国医疗器械法规下获得 CE 和 UKCA 标志，并符合严格的监管标准，确保其安全性、有效性和符合所有适用要求。这款智能数字健康婴儿监测设备舒适地包裹在婴儿的脚上，实时监测脉率、血氧饱和度、睡眠模式等。连接的 Owlet Dream 应用程序（适用于 iOS 和 Android）将实时健康数据直接传送到移动设备和包含的基站，如果婴儿脉率过低/过高或血氧饱和度过低，用户将立即收到通知。经临床验证，能够准确跟踪和显示婴儿的生命体征，适用于 0-18 个月和 2.5-13.6 公斤的健康婴儿。Dream Sock 还可以与 Owlet Cam® 2 配对，让看护人员可以随时从任何地方看到和听到婴儿，接收运动通知等。</p>
<p>Dream Sock 现已在英国和部分欧洲市场上市。Dream Sock 将在接下来的几周内通过 Owlet 的本地化网站和主要零售商在以下市场上市：波兰、捷克共和国、斯洛伐克、匈牙利、罗马尼亚、保加利亚和希腊。</p>
<p><strong>关于 Owlet 公司</strong> Owlet 的数字健康婴儿监测平台正在改变育儿之旅。该公司（NYSE:OWLT）是一家小型医疗保健成长股权公司，提供经 FDA 授权的医疗和消费类儿科可穿戴设备，以及一体化的高清视听摄像头，为父母提供实时数据和见解，以确保他们的孩子健康、优化福祉并保证安宁的睡眠。</p>
<p>自 2012 年以来，全球已有 200 多万父母使用了 Owlet 的平台，为消费者婴儿健康和睡眠数据贡献了最大的数据集之一。该公司继续开发软件和数字数据解决方案，弥合医院和家庭之间当前的医疗差距，并为全球父母和看护人员带来新的见解。Owlet 相信每个孩子都应该过上健康快乐的生活。欲了解更多信息，请访问 www.owletcare.com。</p>
<p><strong>前瞻性声明</strong> 本新闻稿包含根据 1995 年《私人证券诉讼改革法案》（“改革法案”）的前瞻性声明。本新闻稿中所有与历史事实无关的声明都应被视为前瞻性声明，包括但不限于关于公司在欧洲市场认证和推出 Dream Sock 以及国际市场的影响、增长前景、扩大产品系列和产品供应的声明。在某些情况下，您可以通过诸如 “估计”、“可能”、“相信”、“计划”、“期望”、“预期”、“打算”、“目标”、“潜在”、“即将到来”、“展望”、“指导” 等术语来识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。前瞻性声明基于公司在发表这些声明时的期望，仅于发表时生效，并容易受到多种风险、不确定性和其他因素的影响。对于所有此类前瞻性声明，公司均声称受到《改革法案》中关于前瞻性声明的安全港的保护。公司的实际结果、业绩或成就可能会与我们的前瞻性声明中表达或暗示的任何未来结果、业绩或成就有实质性差异。许多重要因素可能会影响公司的未来结果，并导致这些结果与公司的前瞻性声明中表达或暗示的结果有实质性差异。这些因素包括但不限于：（i）Dream Sock 及其新医疗技术在其他国际市场的可用性、采用情况和商业成功，（ii）公司产品的监管途径，包括向 FDA 等监管机构提交申请、监管机构采取的行动以及监管机构作出的决定和回应，以及公司获得和保持产品的监管批准或认证以及其他监管要求和法律诉讼；（iii）公司涉及的诉讼进展，包括公司在美国证券交易委员会（“SEC”）提交的报告中描述的 Butala 和 Cherian 案件；（iv）公司维持其 A 类普通股在国家证券交易所上市的能力，包括通过在 SEC 提交的报告中描述的公司在纽约证券交易所上市公司手册第 802.01B 条款规定的规定期限内恢复合规来维持上市；（v）公司的竞争以及公司实现盈利增长和管理增长的能力；（vi）公司增强未来运营和财务结果或获得额外融资以继续作为持续经营的能力；（vii）公司目前的贷款和债务协议的风险，包括遵守债务契约、限制公司获取资本的限制、公司整体债务水平的影响以及公司生成足够未来现金流以满足公司的债务偿付义务和经营业务的能力；（viii）公司实施战略举措、降低成本、增长收入、开发和推出新产品、创新和增强现有产品、满足客户需求并适应消费者偏好和零售趋势的能力；（ix）公司维护、捍卫和保护其知识产权并满足监管要求，包括但不限于涉及隐私和数据保护、违规和丢失的要求，以及与公司数字平台和技术相关的其他风险；（x）公司与客户、制造商和供应商保持关系并留住 Owlet 的管理层和关键员工的能力；（xi）公司升级和维护其信息技术系统的能力；（xii）适用法律或法规的变化；（xiii）由于公司无法控制的经济和其他条件，如健康流行病或大流行病、宏观经济不确定性、社会动荡、敌对行动、自然灾害或其他灾难性事件对公司业务、财务状况、运营、供应链和物流的影响和中断；（xiv）公司可能受到其他经济、商业、监管、竞争或其他因素的不利影响，如离散消费支出和消费者偏好的变化；以及（xv）公司在其其他发布、公开声明和向 SEC 提交的文件中列明的其他风险和不确定性，包括公司 2023 年 12 月 31 日结束的财年年度报告 Form 10-K 中 “风险因素” 部分、随后的季度报告 Form 10-Q 以及向 SEC 提交的任何当前或定期报告中确定的风险。所有此类归属于公司或代表公司行事的人的前瞻性声明均完全受到上述警示性声明的限制。此外，公司运营在不断发展的环境中。新的风险因素和不确定性可能不时出现，公司目前认为不重要的因素可能变得重要，公司无法预测此类事件或它们可能如何影响公司。除法律要求外，公司不承诺在本新闻稿日期后更新任何前瞻性声明，无论是因为新信息、未来事件还是其他原因，尽管公司可能不时这样做。公司不认可第三方可能提出的关于未来业绩的任何预测。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNDA5MDM5NzE0OTByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNDA5MDM5NzE0OTByMQ"/></p>
<p>在 businesswire.com 上查看源版本: https://www.businesswire.com/news/home/20240903971490/en/</p>
<p><strong>媒体联系：</strong> pr@owletcare.com</p>
<p>来源: Owlet, Inc.</p>

OWLT

<p>Owlet, Inc.宣布在 2024 年的 Kind + Jugend 展会上扩大了其经过医学认证的 Dream Sock 在欧洲的销售范围。该设备将在波兰、希腊、捷克共和国等国家上市，为父母提供实时监测婴儿健康状况的功能。Dream Sock 获得了 CE 和 UKCA 认证，并能准确测量脉率和血氧水平。Owlet 的目标是通过其数字健康婴儿监测平台增强育儿体验，自全球推出以来已经影响了成千上万个家庭</p>

<p>09/03/2024 - 09:41 AM</p>
<div class="lb-trans"><p>09/03/2024 - 上午 09:41</p>
</div><p><em>Owlet debuts new Dream Sock at Kind + Jugend 2024 and shares that the device will soon be available to even more parents across the globe.</em></p>
<div class="lb-trans"><p><em>Owlet 在 Kind + Jugend 2024 展会上推出新款 Dream Sock，并表示该设备将很快在全球更多地区推出。</em></p>
</div><p>LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, announced today at Kind + Jugend in Cologne, Germany, that medically-certified Dream Sock will soon be available in even more countries, including Poland, Greece, and the Czech Republic. Dream Sock is the Company’s medically-certified baby monitor accessible across Europe, giving parents safe and accurate health readings and actionable alarms while their baby sleeps.</p>
<div class="lb-trans"><p>犹他州 LEHI--(商业线)--Owlet 公司（“Owlet” 或 “公司”）（NYSE:OWLT），智能婴儿监测的先驱者，今天在德国科隆举行的 Kind + Jugend 展会上宣布，医疗认证的 Dream Sock 将很快在更多国家推出，包括波兰、希腊和捷克共和国。Dream Sock 是该公司在欧洲推出的医疗认证婴儿监测器，为父母在婴儿睡眠时提供安全准确的健康数据和可操作的警报。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20240903971490/en/2231017/4/dream_sock_2.jpg" alt="" original-src="https://mms.businesswire.com/media/20240903971490/en/2231017/4/dream_sock_2.jpg"/></p>
<p>Owlet Dream Sock (Photo: Business Wire)</p>
<div class="lb-trans"><p>Owlet Dream Sock（图片：商业线）</p>
</div><p>“Dream Sock has already made a huge impact on thousands of families since its global launch a few months ago, and we are eager to continue the roll-out of our medical-grade technology to even more parents,” said Kurt Workman, Owlet Chief Executive Officer and Co-Founder. “We are attending Kind + Jugend this week to meet with current and potential distribution partners to demonstrate our latest technology and show the impact Owlet is having across the world.”</p>
<div class="lb-trans"><p>Owlet 首席执行官兼联合创始人 Kurt Workman 表示：“自全球推出几个月以来，Dream Sock 已经对成千上万个家庭产生了巨大影响，我们渴望继续将我们的医疗级技术推广给更多父母。我们本周参加 Kind + Jugend 展会，与现有和潜在的分销合作伙伴会面，展示我们的最新技术，并展示 Owlet 在全球产生的影响。”</p>
</div><p>Dream Sock is CE and UKCA Marked under EU and UK Medical Device Regulations and meets rigorous regulatory standards, ensuring its safety, efficacy, and compliance with all applicable requirements. This smart digital health infant monitoring device comfortably wraps around Baby's foot, providing real-time monitoring of pulse rate, oxygen saturation level, sleep patterns, and more. The connected Owlet Dream App (available on iOS and Android) delivers live health readings directly to mobile devices and the included Base Station – both of which will immediately notify users if Baby has low/high pulse rate, or low oxygen. It is clinically proven to accurately track and display an infant’s vital signs and is intended for healthy infants between 0-18 months and 2.5-13.6 kg. Dream Sock can also be paired with the Owlet Cam® 2 allowing caregivers to see and hear Baby from anywhere, receive motion notifications, and more.</p>
<div class="lb-trans"><p>Dream Sock 在欧盟和英国医疗器械法规下获得 CE 和 UKCA 标志，并符合严格的监管标准，确保其安全性、有效性和符合所有适用要求。这款智能数字健康婴儿监测设备舒适地包裹在婴儿的脚上，实时监测脉率、血氧饱和度、睡眠模式等。连接的 Owlet Dream 应用程序（适用于 iOS 和 Android）将实时健康数据直接传送到移动设备和包含的基站，如果婴儿脉率过低/过高或血氧饱和度过低，用户将立即收到通知。经临床验证，能够准确跟踪和显示婴儿的生命体征，适用于 0-18 个月和 2.5-13.6 公斤的健康婴儿。Dream Sock 还可以与 Owlet Cam® 2 配对，让看护人员可以随时从任何地方看到和听到婴儿，接收运动通知等。</p>
</div><p>Dream Sock is available now for purchase in the UK and select European markets. Dream Sock will be available in the following markets via Owlet’s localized websites and key retailers in the coming weeks: Poland, the Czech Republic, Slovakia, Hungary, Romania, Bulgaria, and Greece.</p>
<div class="lb-trans"><p>Dream Sock 现已在英国和部分欧洲市场上市。Dream Sock 将在接下来的几周内通过 Owlet 的本地化网站和主要零售商在以下市场上市：波兰、捷克共和国、斯洛伐克、匈牙利、罗马尼亚、保加利亚和希腊。</p>
</div><p><strong>About Owlet, Inc.</strong> Owlet’s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE:OWLT), a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.</p>
<div class="lb-trans"><p><strong>关于 Owlet 公司</strong> Owlet 的数字健康婴儿监测平台正在改变育儿之旅。该公司（NYSE:OWLT）是一家小型医疗保健成长股权公司，提供经 FDA 授权的医疗和消费类儿科可穿戴设备，以及一体化的高清视听摄像头，为父母提供实时数据和见解，以确保他们的孩子健康、优化福祉并保证安宁的睡眠。</p>
</div><p>Since 2012, over 2 million parents worldwide have used Owlet’s platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life. To learn more, visit www.owletcare.com.</p>
<div class="lb-trans"><p>自 2012 年以来，全球已有 200 多万父母使用了 Owlet 的平台，为消费者婴儿健康和睡眠数据贡献了最大的数据集之一。该公司继续开发软件和数字数据解决方案，弥合医院和家庭之间当前的医疗差距，并为全球父母和看护人员带来新的见解。Owlet 相信每个孩子都应该过上健康快乐的生活。欲了解更多信息，请访问 www.owletcare.com。</p>
</div><p><strong>Forward-Looking Statements</strong> This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s certification and launch of its Dream Sock in the European Market and the impacts, growth prospects, and expanded product offerings and product availability in international markets. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the availability of, adoption and commercial success of Dream Sock and its new medical technology within additional international markets, (ii) the regulatory pathway for the Company’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as the Company’s ability to obtain and maintain regulatory approval or certification for our products and other regulatory requirements and legal proceedings; (iii) any developments in litigation in which the Company is involved, including the <em>Butala</em> and <em>Cherian</em> cases described in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”); (iv) the ability of the Company to maintain listing of its Class A common stock on a national stock exchange, including by coming back into compliance with Section 802.01B of the NYSE Listed Company Manual within the allotted cure period described in the Company’s reports filed with the SEC; (v) the Company’s competition and the Company’s ability to profitably grow and manage growth; (vi) the Company’s ability to enhance future operating and financial results or obtain additional financing to continue as a going concern; (vii) risks associated with the Company’s current loan and debt agreements, including compliance with debt covenants, restrictions on the Company’s access to capital, the impact of the Company’s overall debt levels and the Company’s ability to generate sufficient future cash flows to meet the Company’s debt service obligations and operate its business; (viii) the ability of the Company to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (ix) the Company’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements, including but not limited to requirements concerning privacy and data protection, breaches and loss, as well as other risks associated with the Company’s digital platforms and technologies; (x) the Company’s ability to maintain relationships with customers, manufacturers and suppliers and retain Owlet’s management and key employees; (xi) the Company’s ability to upgrade and maintain its information technology systems; (xii) changes in applicable laws or regulations; (xiii) the impact of and disruption to the Company’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control, such as health epidemics or pandemics, macro-economic uncertainties, social unrest, hostilities, natural disasters or other catastrophic events; (xiv) the possibility that the Company may be adversely affected by other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the SEC, including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, and any current or periodic reports filed with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and the Company can't predict such events or how they may affect the Company. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although the Company may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.</p>
<div class="lb-trans"><p><strong>前瞻性声明</strong> 本新闻稿包含根据 1995 年《私人证券诉讼改革法案》（“改革法案”）的前瞻性声明。本新闻稿中所有与历史事实无关的声明都应被视为前瞻性声明，包括但不限于关于公司在欧洲市场认证和推出 Dream Sock 以及国际市场的影响、增长前景、扩大产品系列和产品供应的声明。在某些情况下，您可以通过诸如 “估计”、“可能”、“相信”、“计划”、“期望”、“预期”、“打算”、“目标”、“潜在”、“即将到来”、“展望”、“指导” 等术语来识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。前瞻性声明基于公司在发表这些声明时的期望，仅于发表时生效，并容易受到多种风险、不确定性和其他因素的影响。对于所有此类前瞻性声明，公司均声称受到《改革法案》中关于前瞻性声明的安全港的保护。公司的实际结果、业绩或成就可能会与我们的前瞻性声明中表达或暗示的任何未来结果、业绩或成就有实质性差异。许多重要因素可能会影响公司的未来结果，并导致这些结果与公司的前瞻性声明中表达或暗示的结果有实质性差异。这些因素包括但不限于：（i）Dream Sock 及其新医疗技术在其他国际市场的可用性、采用情况和商业成功，（ii）公司产品的监管途径，包括向 FDA 等监管机构提交申请、监管机构采取的行动以及监管机构作出的决定和回应，以及公司获得和保持产品的监管批准或认证以及其他监管要求和法律诉讼；（iii）公司涉及的诉讼进展，包括公司在美国证券交易委员会（“SEC”）提交的报告中描述的 Butala 和 Cherian 案件；（iv）公司维持其 A 类普通股在国家证券交易所上市的能力，包括通过在 SEC 提交的报告中描述的公司在纽约证券交易所上市公司手册第 802.01B 条款规定的规定期限内恢复合规来维持上市；（v）公司的竞争以及公司实现盈利增长和管理增长的能力；（vi）公司增强未来运营和财务结果或获得额外融资以继续作为持续经营的能力；（vii）公司目前的贷款和债务协议的风险，包括遵守债务契约、限制公司获取资本的限制、公司整体债务水平的影响以及公司生成足够未来现金流以满足公司的债务偿付义务和经营业务的能力；（viii）公司实施战略举措、降低成本、增长收入、开发和推出新产品、创新和增强现有产品、满足客户需求并适应消费者偏好和零售趋势的能力；（ix）公司维护、捍卫和保护其知识产权并满足监管要求，包括但不限于涉及隐私和数据保护、违规和丢失的要求，以及与公司数字平台和技术相关的其他风险；（x）公司与客户、制造商和供应商保持关系并留住 Owlet 的管理层和关键员工的能力；（xi）公司升级和维护其信息技术系统的能力；（xii）适用法律或法规的变化；（xiii）由于公司无法控制的经济和其他条件，如健康流行病或大流行病、宏观经济不确定性、社会动荡、敌对行动、自然灾害或其他灾难性事件对公司业务、财务状况、运营、供应链和物流的影响和中断；（xiv）公司可能受到其他经济、商业、监管、竞争或其他因素的不利影响，如离散消费支出和消费者偏好的变化；以及（xv）公司在其其他发布、公开声明和向 SEC 提交的文件中列明的其他风险和不确定性，包括公司 2023 年 12 月 31 日结束的财年年度报告 Form 10-K 中 “风险因素” 部分、随后的季度报告 Form 10-Q 以及向 SEC 提交的任何当前或定期报告中确定的风险。所有此类归属于公司或代表公司行事的人的前瞻性声明均完全受到上述警示性声明的限制。此外，公司运营在不断发展的环境中。新的风险因素和不确定性可能不时出现，公司目前认为不重要的因素可能变得重要，公司无法预测此类事件或它们可能如何影响公司。除法律要求外，公司不承诺在本新闻稿日期后更新任何前瞻性声明，无论是因为新信息、未来事件还是其他原因，尽管公司可能不时这样做。公司不认可第三方可能提出的关于未来业绩的任何预测。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNDA5MDM5NzE0OTByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20240903971490r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20240903971490/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本: https://www.businesswire.com/news/home/20240903971490/en/</p>
</div><p><strong>Media:</strong> pr@owletcare.com</p>
<div class="lb-trans"><p><strong>媒体联系：</strong> pr@owletcare.com</p>
</div><p>Source: Owlet, Inc.</p>
<div class="lb-trans"><p>来源: Owlet, Inc.</p>
</div>

Owlet 宣布在欧洲扩大医疗认证的 Dream SockTM 的供应范围 | OWLT 股票新闻